A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
Conclusions:
Taking the results of DiaRegis into consideration it can be concluded that incretin-based treatment strategies appear to have a favourable balance between glycemic control and treatment emergent adverse effects.
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Anselm GittPeter BramlageSteffen SchneiderDiethelm Tschöpe Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Incretin Therapy | Insulin | Metformin